0

Global Coronary Artery Disease Therapeutics Market 2017-2021

  • Published: Oct 2017
  • Pages: 100
  • SKU: IRTNTR15496
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This market research study identifies AstraZeneca, Gilead, Novartis, and Pfizer as the leading players in the global coronary artery disease therapeutics market. A comprehensive analysis of this market is also presented by drug class (beta-blockers, calcium channel blockers, nitrates, ACE inhibitors, and others) and by geography (the Americas, APAC, and EMEA). 

Overview of the global coronary artery disease therapeutics market

The incidence of chronic diseases such as diabetes, obesity, and high blood pressure is increasing across the globe. This creates a huge economic burden on the global healthcare system. Our research analysis on the global coronary artery disease therapeutics market has identified that the increase in the number of chronic diseases will be one of the major factors that will have a positive impact on this market’s growth during the next few years. A large number of patients are experiencing a low quality of life due to the uncontrolled blood sugar level. This can result in death. The lack of awareness and treatment facilities in Africa is resulting in an increased number of diabetic patients. According to the studies, countries such as China, India, and the US have the largest number of diabetic patients. This will further boost the demand for coronary artery disease therapeutics. Based on the coronary artery disease therapeutics industry analysis, this market will grow at a CAGR of more than 5% by 2021.

The fragmented nature of the market results in a division of profits among too many participants. This leaves the participants with minimal economic benefits. As a result, the coronary artery disease therapeutics market is witnessing a growth in the number of strategic alliances and acquisitions. In addition to acquisitions, the vendors are also focusing on entering into partnerships and are also forming joint ventures to develop new and better drugs.

Competitive landscape and key vendors

The coronary artery disease therapeutics market is highly competitive and is characterized by the presence of a large number of large, small, and medium-sized vendors. The vendors are increasingly competing against each other based on factors such as aggressive pricing, product efficacy, limited side effects, rich pipeline, and operational base. The rise in the number of mergers and acquisitions, product extensions, and the rising investments in R&D activities will strengthen the market’s competitive environment.

Key vendors in this market are 

  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer

Other prominent vendors in the market include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Mylan, and Teva Pharmaceutical Industries

Segmentation by drug class and analysis of the coronary artery disease therapeutics market

  • Beta-blockers
  • Calcium channel blockers
  • Nitrates
  • ACE inhibitors

Beta-blockers drugs reduce the blood pressure and heart rate by blocking the effect of stress hormones such as adrenaline. Acebutolol, atenolol, carvedilol, labetalol, metoprolol, penbutolol, pindolol, and propranolol are some of the common beta-blockers that are used for the treatment of cardiovascular diseases. The beta-blockers drug class is highly preferred over other drug classes because they enable the damaged heart to work more effectively. This, in turn, will stimulate the coronary artery disease treatment market growth in this segment.

Segmentation by geography and analysis of the coronary artery disease therapeutics market

  • Americas
  • APAC
  • EMEA

Based on the coronary artery disease therapeutics market regional outlook, the consumption of drugs for cardiovascular disease (CAD) in the Americas is increasing due to the rising incidences of heart disease in the region. The region is heavily investing in the healthcare sector, which in turn, will drive the coronary artery disease therapeutics market’s growth in the region. The US is the major revenue generator in the region due to the presence of the pharmaceutical giants and the high prevalence rate of CAD.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global coronary artery disease therapeutics market?
  • What are the key market trends impacting the growth of the global coronary artery disease therapeutics market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global coronary artery disease therapeutics market?
  • What are the market opportunities and threats faced by the vendors in the global coronary artery disease therapeutics market?
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
  • What are the key outcomes of the five forces analysis of the global coronary artery disease therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

 

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline
  • Disease definition
  • Risk factors for CAD
  • Diagnosis
  • Treatment options

PART 05: MARKET LANDSCAPE

  • Market overview
  • Five forces analysis

PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY DRUG CLASS

  • Comparison by drug class
  • Beta-blockers
  • Calcium channel blockers
  • Nitrates
  • ACE inhibitors
  • Others
  • Market opportunity

PART 08: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • CAD therapeutics in Americas
  • CAD therapeutics in EMEA
  • CAD therapeutics in APAC
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Growing strategic alliances
  • Investment inclination toward developing countries

PART 12: VENDOR LANDSCAPE

  • Competitive landscape

PART 13: VENDOR ANALYSIS

  • Vendor overview

PART 14: KEY VENDORS

  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer

PART 15: APPENDIX

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>